These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24551591)

  • 1. Syndecans as modulators and potential pharmacological targets in cancer progression.
    Barbouri D; Afratis N; Gialeli C; Vynios DH; Theocharis AD; Karamanos NK
    Front Oncol; 2014; 4():4. PubMed ID: 24551591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities.
    Agere SA; Kim EY; Akhtar N; Ahmed S
    J Cell Physiol; 2018 Sep; 233(9):6346-6358. PubMed ID: 29226950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shed proteoglycans in tumor stroma.
    Piperigkou Z; Mohr B; Karamanos N; Götte M
    Cell Tissue Res; 2016 Sep; 365(3):643-55. PubMed ID: 27365088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecans and Enzymes for Heparan Sulfate Biosynthesis and Modification Differentially Correlate With Presence of Inflammatory Infiltrate in Periodontitis.
    Duplancic R; Roguljic M; Puhar I; Vecek N; Dragun R; Vukojevic K; Saraga-Babic M; Kero D
    Front Physiol; 2019; 10():1248. PubMed ID: 31611818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecans and Enzymes Involved in Heparan Sulfate Biosynthesis and Degradation Are Differentially Expressed During Human Odontogenesis.
    Kero D; Bilandzija TS; Arapovic LL; Vukojevic K; Saraga-Babic M
    Front Physiol; 2018; 9():732. PubMed ID: 29962964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan Sulfate in the Tumor Microenvironment.
    Bartolini B; Caravà E; Caon I; Parnigoni A; Moretto P; Passi A; Vigetti D; Viola M; Karousou E
    Adv Exp Med Biol; 2020; 1245():147-161. PubMed ID: 32266657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.
    Hammond E; Khurana A; Shridhar V; Dredge K
    Front Oncol; 2014; 4():195. PubMed ID: 25105093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
    Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
    J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndecans in heart fibrosis.
    Lunde IG; Herum KM; Carlson CC; Christensen G
    Cell Tissue Res; 2016 Sep; 365(3):539-52. PubMed ID: 27411689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-molecule force spectroscopy reveals structural differences of heparan sulfate chains during binding to vitronectin.
    Herman K; Zemła J; Ptak A; Lekka M
    Phys Rev E; 2021 Aug; 104(2-1):024409. PubMed ID: 34525582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-Dimensional Human Neural Stem Cell Models to Mimic Heparan Sulfate Proteoglycans and the Neural Niche.
    Peall IW; Okolicsanyi RK; Griffiths LR; Haupt LM
    Semin Thromb Hemost; 2021 Apr; 47(3):308-315. PubMed ID: 33794554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
    Lanzi C; Cassinelli G
    Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing the metastatic potential in cancers--targeting the heparan sulfate proteoglycans.
    Fjeldstad K; Kolset SO
    Curr Drug Targets; 2005 Sep; 6(6):665-82. PubMed ID: 16178800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.
    Sanderson RD; Yang Y; Kelly T; MacLeod V; Dai Y; Theus A
    J Cell Biochem; 2005 Dec; 96(5):897-905. PubMed ID: 16149080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression.
    Nagarajan A; Malvi P; Wajapeyee N
    Front Endocrinol (Lausanne); 2018; 9():483. PubMed ID: 30197623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling.
    Lopes CC; Dietrich CP; Nader HB
    Braz J Med Biol Res; 2006 Feb; 39(2):157-67. PubMed ID: 16470302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutual Inhibition of Antithrombin III and SARS-CoV-2 Cellular Attachment to Syndecans: Implications for COVID-19 Treatment and Vaccination.
    Hudák A; Pusztai D; Letoha A; Letoha T
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecans in Inflammation at a Glance.
    Gopal S
    Front Immunol; 2020; 11():227. PubMed ID: 32133006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma.
    Motta JM; Hassan H; Ibrahim SA
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance.
    Lanzi C; Zaffaroni N; Cassinelli G
    Curr Med Chem; 2017; 24(26):2860-2886. PubMed ID: 28215163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.